AR048191A1 - Expresion optimizada de hpv 52 l1 en levaduras - Google Patents

Expresion optimizada de hpv 52 l1 en levaduras

Info

Publication number
AR048191A1
AR048191A1 ARP050101174A ARP050101174A AR048191A1 AR 048191 A1 AR048191 A1 AR 048191A1 AR P050101174 A ARP050101174 A AR P050101174A AR P050101174 A ARP050101174 A AR P050101174A AR 048191 A1 AR048191 A1 AR 048191A1
Authority
AR
Argentina
Prior art keywords
hpv
vlps
synthetic
protein
produce
Prior art date
Application number
ARP050101174A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR048191A1 publication Critical patent/AR048191A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona moléculas de DNA sintético que codifican la proteína HPV 52 L1. Específicamente, se proporciona polinucleotidos que codifican la proteína HPV 52 L1, donde dichos polinucleotidos están codon-optimizados para una alto nivel de expresion en una célula de levadura. Entre otros, la secuencia de nucleotidos de la molécula sintética se altera para eliminar las senales de terminacion de la transcripcion que son reconocidas por la levadura. Las moléculas sintéticas pueden ser utilizadas para producir partículas semejantes a virus (VLPs) HPV 52, y para producir vacunas y composiciones farmacéuticas que comprende las VLPs HPV 52. Dichas vacunas proporcionan una inmunoprofilaxis efectiva contra la infeccion de papilomavirus a través de la neutralizacion de anticuerpos e inmunidad mediada por células y puede también ser util para el tratamiento de las infecciones existentes de HPV.
ARP050101174A 2004-03-24 2005-03-23 Expresion optimizada de hpv 52 l1 en levaduras AR048191A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55592604P 2004-03-24 2004-03-24

Publications (1)

Publication Number Publication Date
AR048191A1 true AR048191A1 (es) 2006-04-05

Family

ID=34964085

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101174A AR048191A1 (es) 2004-03-24 2005-03-23 Expresion optimizada de hpv 52 l1 en levaduras

Country Status (31)

Country Link
US (2) US7700103B2 (es)
EP (1) EP1730175B1 (es)
JP (1) JP4833962B2 (es)
KR (1) KR101203403B1 (es)
CN (1) CN1934131B (es)
AR (1) AR048191A1 (es)
AT (1) ATE466022T1 (es)
AU (1) AU2005230907C1 (es)
BE (1) BE2015C066I2 (es)
BR (1) BRPI0509079B8 (es)
CA (1) CA2560487C (es)
CY (2) CY1110349T1 (es)
DE (1) DE602005020913D1 (es)
DK (1) DK1730175T3 (es)
ES (1) ES2343255T3 (es)
FR (1) FR15C0085I2 (es)
HU (1) HUS1500062I1 (es)
IL (1) IL178140A (es)
LT (2) LTPA2015050I1 (es)
LU (1) LU92903I2 (es)
MY (1) MY148656A (es)
NL (1) NL300777I1 (es)
NO (3) NO338055B1 (es)
NZ (1) NZ549898A (es)
PL (1) PL1730175T3 (es)
PT (1) PT1730175E (es)
RU (1) RU2373219C2 (es)
SI (1) SI1730175T1 (es)
TW (1) TWI349036B (es)
WO (1) WO2005097821A1 (es)
ZA (1) ZA200607575B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
CN1869215B (zh) * 2006-05-19 2012-07-04 长春百克生物科技股份公司 一种制备人乳头瘤病毒的病毒样颗粒的方法
EP2129394B1 (en) 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
MY182347A (en) 2007-11-23 2021-01-20 Shanghai Zerun Biotechnology Co Ltd Genes encoding major capsid protein l1 of human papilloma virus and use of the same
CN101440371B (zh) * 2007-11-23 2012-09-05 上海泽润生物科技有限公司 一种16型人乳头状瘤病毒主要衣壳蛋白l1基因
CN107641151B (zh) * 2010-05-14 2021-10-01 百深公司 Ospa嵌合体及其在疫苗中的用途
US9376727B2 (en) 2010-05-25 2016-06-28 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically truncated probes
WO2012000454A1 (zh) * 2010-07-02 2012-01-05 厦门大学 截短的人乳头瘤病毒52型l1蛋白
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
EP2646559A2 (en) 2010-12-03 2013-10-09 MS Technologies, LLC Optimized expression of glyphosate resistance encoding nucleic acid molecules in plant cells
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
RU2445357C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16
RU2445358C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18
CN104120089B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN110592133A (zh) * 2013-05-17 2019-12-20 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
EP3057612B1 (en) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
CN104878022A (zh) * 2015-04-27 2015-09-02 段青姣 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用
CN106701796B (zh) * 2015-08-12 2021-11-16 北京康乐卫士生物技术股份有限公司 52型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750049B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒52亚型蛋白表达
EP4103227A1 (en) 2020-02-14 2022-12-21 Merck Sharp & Dohme LLC Hpv vaccine
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
CN113549634B (zh) * 2021-06-07 2023-03-31 郑州大学 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用
US20230048144A1 (en) 2021-08-06 2023-02-16 Merck Sharp & Dohme Llc Hpv vaccine
CN118019547A (zh) 2021-08-19 2024-05-10 默沙东有限责任公司 热稳定脂质纳米粒子及其使用方法
KR20260021734A (ko) 2023-06-09 2026-02-13 머크 샤프 앤드 돔 엘엘씨 인간 유두종바이러스 백신을 위한 나노에멀젼 아주반트 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339729C (en) * 1988-10-26 1998-03-17 Wayne D. Lancaster Human papillomavirus type 52 dna sequences and methods for employing thesame
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5821087A (en) 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
EP0969862B1 (en) 1997-02-07 2006-10-18 Merck & Co., Inc. Synthetic hiv gag genes
EP1002091B1 (en) 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
EP1105157B1 (en) 1998-08-14 2006-11-02 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
BR9913026A (pt) * 1998-08-14 2001-09-25 Merck & Co Inc Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
JP4799789B2 (ja) * 1999-08-25 2011-10-26 メルク・シャープ・エンド・ドーム・コーポレイション ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
DE60124918T2 (de) 2000-07-21 2007-08-02 Glaxo Group Ltd., Greenford Kodon-optimierte papillomavirussequenzen
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
ES2381964T3 (es) 2003-03-24 2012-06-04 Merck Sharp & Dohme Corp. Expresión optimizada de L1 de VPH 31 en levadura
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast

Also Published As

Publication number Publication date
EP1730175A1 (en) 2006-12-13
FR15C0085I1 (es) 2016-08-01
IL178140A (en) 2010-11-30
EP1730175B1 (en) 2010-04-28
FR15C0085I2 (fr) 2016-11-25
HUS1500062I1 (hu) 2017-07-28
JP2007530040A (ja) 2007-11-01
CN1934131B (zh) 2010-12-29
US20100035818A1 (en) 2010-02-11
KR20060134120A (ko) 2006-12-27
NO2017005I1 (no) 2017-01-20
US7744892B2 (en) 2010-06-29
ATE466022T1 (de) 2010-05-15
CA2560487C (en) 2013-01-29
US20080226660A1 (en) 2008-09-18
AU2005230907B2 (en) 2011-05-19
RU2006137363A (ru) 2008-04-27
CA2560487A1 (en) 2005-10-20
BRPI0509079B1 (pt) 2020-05-19
TW200602490A (en) 2006-01-16
CY1110349T1 (el) 2015-04-29
BE2015C066I2 (es) 2024-08-08
BRPI0509079B8 (pt) 2021-07-06
RU2373219C2 (ru) 2009-11-20
AU2005230907C1 (en) 2016-07-28
CY2015052I2 (el) 2016-06-22
JP4833962B2 (ja) 2011-12-07
MY148656A (en) 2013-05-15
NO2022050I1 (no) 2022-11-30
LTPA2015050I1 (lt) 2016-01-11
LU92903I2 (fr) 2016-03-08
DE602005020913D1 (de) 2010-06-10
BRPI0509079A (pt) 2007-08-21
LTC1730175I2 (lt) 2017-05-10
NO338055B1 (no) 2016-07-25
PT1730175E (pt) 2010-06-25
NL300777I2 (es) 2015-12-29
WO2005097821A1 (en) 2005-10-20
IL178140A0 (en) 2006-12-31
DK1730175T3 (da) 2010-08-23
NZ549898A (en) 2009-06-26
US7700103B2 (en) 2010-04-20
CY2015052I1 (el) 2016-06-22
CN1934131A (zh) 2007-03-21
KR101203403B1 (ko) 2012-11-21
AU2005230907A1 (en) 2005-10-20
SI1730175T1 (sl) 2010-08-31
ES2343255T3 (es) 2010-07-27
TWI349036B (en) 2011-09-21
PL1730175T3 (pl) 2010-09-30
NL300777I1 (es) 2015-12-29
ZA200607575B (en) 2008-08-27
NO20064815L (no) 2006-10-23

Similar Documents

Publication Publication Date Title
AR048191A1 (es) Expresion optimizada de hpv 52 l1 en levaduras
AR046835A1 (es) Expresion optimizada de l1 de hpv58 en levadura
NO2018010I1 (no) HPV 31 L1 protein
AR045804A1 (es) Expresion optimizada de l1 del vph45 en levaduras
DE60016765D1 (de) Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
SG131116A1 (en) Functional influenza virus-like particles (vlps)
US20140288283A1 (en) Truncated l1 protein of human papillomavirus type 6
Zhao et al. Enterovirus71 virus‐like particles produced from insect cells and purified by multistep chromatography elicit strong humoral immune responses in mice
CN102336822A (zh) 截短的人乳头瘤病毒58型l1蛋白
EP1427443A4 (en) VACCINES WITH PAPILLOMA VIRUS E PROTEINS DELIVERED BY A VIRAL VECTOR
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
CA3242553A1 (en) Compositions and methods for expressing antigens on cell membrane
TW200607858A (en) Optimized expression of HPV 31 L1 in yeast
MY138895A (en) Optimized expression of hpv 31 l1 in yeast
TH82139B (th) การแสดงออกที่ถูกทำให้เหมาะสมของ hpv 45l1 ในยีสต์

Legal Events

Date Code Title Description
FG Grant, registration